{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#####Importing required modules###########\n",
    "import requests\n",
    "import json\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "##to display plot in the jupyter notebook###\n",
    "%matplotlib inline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "Company=\"ASTRAZENECA\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "url=\"https://api.fda.gov/drug/label.json?search=openfda.manufacturer_name:\"+Company"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "r=requests.get(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "r.status_code"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "j_son= r.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['meta', 'results'])"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "j_son.keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'disclaimer': 'Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.',\n",
       " 'last_updated': '2021-08-09',\n",
       " 'license': 'https://open.fda.gov/license/',\n",
       " 'results': {'limit': 1, 'skip': 0, 'total': 36},\n",
       " 'terms': 'https://open.fda.gov/terms/'}"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "j_son['meta']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "###As total no of results are only 36. limit is given as 36#####\n",
    "url_limit=\"https://api.fda.gov/drug/label.json?search=openfda.manufacturer_name:\"+Company+\"&limit=36\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "r_limit=requests.get(url_limit)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "##converting to Json format \n",
    "js=r_limit.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "###flatening the json format###\n",
    "js_n= pd.json_normalize(js.get('results'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 36 entries, 0 to 35\n",
      "Data columns (total 79 columns):\n",
      " #   Column                                                      Non-Null Count  Dtype \n",
      "---  ------                                                      --------------  ----- \n",
      " 0   effective_time                                              36 non-null     object\n",
      " 1   recent_major_changes                                        20 non-null     object\n",
      " 2   drug_interactions                                           34 non-null     object\n",
      " 3   geriatric_use                                               35 non-null     object\n",
      " 4   abuse                                                       2 non-null      object\n",
      " 5   pharmacodynamics                                            34 non-null     object\n",
      " 6   description                                                 36 non-null     object\n",
      " 7   nonclinical_toxicology                                      36 non-null     object\n",
      " 8   warnings_and_cautions_table                                 4 non-null      object\n",
      " 9   dosage_forms_and_strengths                                  36 non-null     object\n",
      " 10  clinical_pharmacology_table                                 13 non-null     object\n",
      " 11  mechanism_of_action                                         36 non-null     object\n",
      " 12  pharmacokinetics_table                                      11 non-null     object\n",
      " 13  pharmacokinetics                                            34 non-null     object\n",
      " 14  clinical_studies_table                                      34 non-null     object\n",
      " 15  indications_and_usage                                       36 non-null     object\n",
      " 16  set_id                                                      36 non-null     object\n",
      " 17  id                                                          36 non-null     object\n",
      " 18  dosage_and_administration_table                             14 non-null     object\n",
      " 19  pediatric_use                                               36 non-null     object\n",
      " 20  contraindications                                           36 non-null     object\n",
      " 21  drug_abuse_and_dependence                                   2 non-null      object\n",
      " 22  pregnancy                                                   36 non-null     object\n",
      " 23  spl_product_data_elements                                   36 non-null     object\n",
      " 24  boxed_warning                                               9 non-null      object\n",
      " 25  warnings_and_cautions                                       36 non-null     object\n",
      " 26  adverse_reactions_table                                     33 non-null     object\n",
      " 27  controlled_substance                                        2 non-null      object\n",
      " 28  version                                                     36 non-null     object\n",
      " 29  dosage_and_administration                                   36 non-null     object\n",
      " 30  adverse_reactions                                           36 non-null     object\n",
      " 31  animal_pharmacology_and_or_toxicology                       13 non-null     object\n",
      " 32  use_in_specific_populations                                 36 non-null     object\n",
      " 33  how_supplied                                                36 non-null     object\n",
      " 34  information_for_patients                                    36 non-null     object\n",
      " 35  clinical_studies                                            36 non-null     object\n",
      " 36  package_label_principal_display_panel                       36 non-null     object\n",
      " 37  spl_medguide                                                18 non-null     object\n",
      " 38  clinical_pharmacology                                       36 non-null     object\n",
      " 39  carcinogenesis_and_mutagenesis_and_impairment_of_fertility  36 non-null     object\n",
      " 40  overdosage                                                  29 non-null     object\n",
      " 41  spl_medguide_table                                          16 non-null     object\n",
      " 42  openfda.application_number                                  36 non-null     object\n",
      " 43  openfda.brand_name                                          36 non-null     object\n",
      " 44  openfda.generic_name                                        36 non-null     object\n",
      " 45  openfda.manufacturer_name                                   36 non-null     object\n",
      " 46  openfda.product_ndc                                         36 non-null     object\n",
      " 47  openfda.product_type                                        36 non-null     object\n",
      " 48  openfda.route                                               36 non-null     object\n",
      " 49  openfda.substance_name                                      36 non-null     object\n",
      " 50  openfda.rxcui                                               32 non-null     object\n",
      " 51  openfda.spl_id                                              36 non-null     object\n",
      " 52  openfda.spl_set_id                                          36 non-null     object\n",
      " 53  openfda.package_ndc                                         36 non-null     object\n",
      " 54  openfda.is_original_packager                                36 non-null     object\n",
      " 55  openfda.unii                                                36 non-null     object\n",
      " 56  spl_patient_package_insert                                  16 non-null     object\n",
      " 57  spl_patient_package_insert_table                            16 non-null     object\n",
      " 58  openfda.nui                                                 20 non-null     object\n",
      " 59  openfda.pharm_class_epc                                     20 non-null     object\n",
      " 60  openfda.pharm_class_moa                                     20 non-null     object\n",
      " 61  instructions_for_use                                        10 non-null     object\n",
      " 62  how_supplied_table                                          11 non-null     object\n",
      " 63  drug_interactions_table                                     8 non-null      object\n",
      " 64  openfda.pharm_class_cs                                      4 non-null      object\n",
      " 65  mechanism_of_action_table                                   1 non-null      object\n",
      " 66  storage_and_handling                                        3 non-null      object\n",
      " 67  instructions_for_use_table                                  7 non-null      object\n",
      " 68  pharmacodynamics_table                                      4 non-null      object\n",
      " 69  storage_and_handling_table                                  1 non-null      object\n",
      " 70  patient_medication_information                              1 non-null      object\n",
      " 71  patient_medication_information_table                        1 non-null      object\n",
      " 72  risks                                                       2 non-null      object\n",
      " 73  spl_unclassified_section                                    1 non-null      object\n",
      " 74  package_label_principal_display_panel_table                 2 non-null      object\n",
      " 75  laboratory_tests                                            3 non-null      object\n",
      " 76  pharmacogenomics                                            1 non-null      object\n",
      " 77  teratogenic_effects                                         2 non-null      object\n",
      " 78  openfda.pharm_class_pe                                      1 non-null      object\n",
      "dtypes: object(79)\n",
      "memory usage: 22.3+ KB\n"
     ]
    }
   ],
   "source": [
    "js_n.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>effective_time</th>\n",
       "      <th>recent_major_changes</th>\n",
       "      <th>drug_interactions</th>\n",
       "      <th>geriatric_use</th>\n",
       "      <th>abuse</th>\n",
       "      <th>pharmacodynamics</th>\n",
       "      <th>description</th>\n",
       "      <th>nonclinical_toxicology</th>\n",
       "      <th>warnings_and_cautions_table</th>\n",
       "      <th>dosage_forms_and_strengths</th>\n",
       "      <th>...</th>\n",
       "      <th>storage_and_handling_table</th>\n",
       "      <th>patient_medication_information</th>\n",
       "      <th>patient_medication_information_table</th>\n",
       "      <th>risks</th>\n",
       "      <th>spl_unclassified_section</th>\n",
       "      <th>package_label_principal_display_panel_table</th>\n",
       "      <th>laboratory_tests</th>\n",
       "      <th>pharmacogenomics</th>\n",
       "      <th>teratogenic_effects</th>\n",
       "      <th>openfda.pharm_class_pe</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20200918</td>\n",
       "      <td>[Warnings and Precautions ( 5.20 ) 09/2020]</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Concomitant use of stro...</td>\n",
       "      <td>[8.5 Geriatric Use Of the approximately 3700 p...</td>\n",
       "      <td>[9.2 Abuse SEROQUEL has not been systematicall...</td>\n",
       "      <td>[12.2 Pharmacodynamics Quetiapine and its meta...</td>\n",
       "      <td>[11 DESCRIPTION SEROQUEL ® (quetiapine) is an ...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>[&lt;table width=\"100%\"&gt;&lt;caption&gt;Table 2: Drug-Pl...</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS • 25 mg tablets ...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20201005</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS There are no known drug-d...</td>\n",
       "      <td>[8.5 Geriatric Use For fulvestrant 250 mg, whe...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In a clinical study in ...</td>\n",
       "      <td>[11 DESCRIPTION FULVESTRANT INJECTION for intr...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS FULVESTRANT INJE...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190724</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS In clinical studies, conc...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of asth...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Asthma Cardiovascular e...</td>\n",
       "      <td>[11 DESCRIPTION BUDESONIDE AND FORMOTEROL FUMA...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>[&lt;table ID=\"_RefID0EKJAE\" width=\"100%\"&gt; &lt;capti...</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS BUDESONIDE AND F...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20210722</td>\n",
       "      <td>[Indications and Usage ( 1 ) 07/2021 Dosage an...</td>\n",
       "      <td>[7 DRUG INTERACTIONS Table 3: Clinically Relev...</td>\n",
       "      <td>[8.5 Geriatric Use In two comparator-controlle...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Exenatide improves glyc...</td>\n",
       "      <td>[11 DESCRIPTION BYDUREON BCISE (exenatide exte...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Extended-release...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20191011</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS Strong Cytochrome P450 3A...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 215 patients in 3 cl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics The therapeutic effects...</td>\n",
       "      <td>[11 DESCRIPTION Budesonide, the active compone...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS PULMICORT RESPUL...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20200124</td>\n",
       "      <td>[Indications and Usage (1) 05/2019 Dosage and ...</td>\n",
       "      <td>[7 DRUG INTERACTIONS Table 2: Clinically Relev...</td>\n",
       "      <td>[8.5 Geriatric Use Because elderly patients ar...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Dapagliflozin Increases...</td>\n",
       "      <td>[11 DESCRIPTION QTERN tablets for oral use con...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Tablets: • 5 mg ...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20200918</td>\n",
       "      <td>[Warnings and Precautions (5.20) 09/2020]</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Concomitant use of stro...</td>\n",
       "      <td>[8.5 Geriatric Use Sixty-eight patients in cli...</td>\n",
       "      <td>[9.2 Abuse SEROQUEL XR has not been systematic...</td>\n",
       "      <td>[12.2 Pharmacodynamics Quetiapine and its meta...</td>\n",
       "      <td>[11 DESCRIPTION SEROQUEL XR (quetiapine) is an...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>[&lt;table width=\"100%\"&gt;&lt;caption&gt;Table 2: Drug-Pl...</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS • 50 mg extended...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20191218</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS 7.1 Insulin The pharmacok...</td>\n",
       "      <td>[8.5 Geriatric Use SYMLIN has been studied in ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In clinical studies in ...</td>\n",
       "      <td>[11 DESCRIPTION SYMLIN ® (pramlintide acetate)...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS SYMLIN is suppli...</td>\n",
       "      <td>...</td>\n",
       "      <td>[&lt;table ID=\"_Reftable9\" width=\"100%\"&gt; &lt;caption...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20210617</td>\n",
       "      <td>[Warnings and Precautions (5.3) . 06/2021]</td>\n",
       "      <td>[7 DRUG INTERACTIONS • May impact absorption o...</td>\n",
       "      <td>[8.5 Geriatric Use Population pharmacokinetic ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Glucose-Dependent Insul...</td>\n",
       "      <td>[11 DESCRIPTION BYETTA (exenatide) is a synthe...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS BYETTA injection...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20191011</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Strong Cytochrome P450 ...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of pati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics To confirm that systemi...</td>\n",
       "      <td>[11 DESCRIPTION Budesonide, the active compone...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS PULMICORT FLEXHA...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20210726</td>\n",
       "      <td>[Indications and Usage ( 1.1 ) 12/2020 Dosage ...</td>\n",
       "      <td>[7 DRUG INTERACTIONS Strong CYP3A Inducers : A...</td>\n",
       "      <td>[8.5 Geriatric Use Forty-three percent (43%) o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Based on an analysis of...</td>\n",
       "      <td>[11 DESCRIPTION Osimertinib is a kinase inhibi...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS 80 mg tablets: b...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20200723</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS No formal drug interactio...</td>\n",
       "      <td>[8.5 Geriatric Use Based on available data, no...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Cardiac Electrophysiolo...</td>\n",
       "      <td>[11 DESCRIPTION BREZTRI AEROSPHERE (budesonide...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Inhalation Aeros...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[PATIENT INFORMATION BREZTRI AEROSPHERE™ (brez...</td>\n",
       "      <td>[&lt;table width=\"100%\"&gt;&lt;col width=\"50%\"/&gt;&lt;col wi...</td>\n",
       "      <td>[Risk Summary There are no adequate and well-c...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20210722</td>\n",
       "      <td>[Indications and Usage ( 1 ) 07/2021 Dosage an...</td>\n",
       "      <td>[7 DRUG INTERACTIONS Table 4: Clinically Relev...</td>\n",
       "      <td>[8.5 Geriatric Use In five comparator-controll...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Exenatide improves glyc...</td>\n",
       "      <td>[11 DESCRIPTION BYDUREON (exenatide extended-r...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Extended-release...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20210510</td>\n",
       "      <td>[Indications and Usage (1) 04/2021 Dosage and ...</td>\n",
       "      <td>[7 DRUG INTERACTIONS 7.1 Positive Urine Glucos...</td>\n",
       "      <td>[8.5 Geriatric Use No FARXIGA dosage change is...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics General Increases in th...</td>\n",
       "      <td>[11 DESCRIPTION Dapagliflozin is described che...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS • FARXIGA 5 mg t...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Distributed by: AstraZeneca Pharmaceuticals L...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20210610</td>\n",
       "      <td>[Indications and Usage (1) 05/2020 Dosage and ...</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Strong or moderate CYP3...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 2351 patients with a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[11 DESCRIPTION Olaparib is a poly (ADP-ribose...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Tablets: • 150 m...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20210520</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Strong or Moderate CYP3...</td>\n",
       "      <td>[8.5 Geriatric Use Clinical studies did not in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics The exposure-response r...</td>\n",
       "      <td>[11 DESCRIPTION Selumetinib is a kinase inhibi...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Capsules: • 10 m...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20210506</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS • CYP3A4 Inducer: Increas...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 823 patients enrolle...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[11 DESCRIPTION Gefitinib is a kinase inhibito...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS 250 mg tablets: ...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20200925</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS There are no known drug-d...</td>\n",
       "      <td>[8.5 Geriatric Use For FASLODEX 250 mg, when t...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In a clinical study in ...</td>\n",
       "      <td>[11 DESCRIPTION FASLODEX ® (fulvestrant) injec...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS FASLODEX, an inj...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[&lt;table width=\"100%\"&gt;&lt;col width=\"39%\"/&gt;&lt;col wi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20210729</td>\n",
       "      <td>[Indications and Usage, Urothelial Carcinoma –...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[8.5 Geriatric Use Of the 476 patients treated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics The steady state AUC, C...</td>\n",
       "      <td>[11 DESCRIPTION Durvalumab is a programmed cel...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Injection: 120 m...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20201022</td>\n",
       "      <td>[Dosage and Administration ( 2.2 ) 4/2020 Warn...</td>\n",
       "      <td>[7 DRUG INTERACTIONS LOKELMA can transiently i...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of subj...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In a study in healthy a...</td>\n",
       "      <td>[11 DESCRIPTION LOKELMA is a powder for oral s...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS For oral suspens...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20200121</td>\n",
       "      <td>[Indications and Usage (1) 10/2019 Dosage and ...</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Carbonic anhydrase inhi...</td>\n",
       "      <td>[8.5 Geriatric Use XIGDUO XR No XIGDUO XR dosa...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics General Dapagliflozin I...</td>\n",
       "      <td>[11 DESCRIPTION XIGDUO XR (dapagliflozin and m...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS XIGDUO XR (dapag...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Laboratory Tests Increases in Serum Creatinin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>20210223</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS In vitro studies suggest ...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 636 COPD patients ex...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Cardiovascular Effects ...</td>\n",
       "      <td>[11 DESCRIPTION TUDORZA PRESSAIR consists of a...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Inhalation Powde...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>20201105</td>\n",
       "      <td>[Indications and Usage ( 1 ) 11/2020]</td>\n",
       "      <td>[7 DRUG INTERACTIONS No formal drug interactio...</td>\n",
       "      <td>[8.5 Geriatric Use Based on available data, no...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Cardiac Electrophysiolo...</td>\n",
       "      <td>[11 DESCRIPTION BEVESPI AEROSPHERE (glycopyrro...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Inhalation aeros...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>20200925</td>\n",
       "      <td>[Dosage and Administration, Use with Concomita...</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Combination of sofosbuv...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 10,275 patients in c...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics CRESTOR dose dependentl...</td>\n",
       "      <td>[11 DESCRIPTION CRESTOR (rosuvastatin calcium)...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS 5 mg: Yellow, ro...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>20201127</td>\n",
       "      <td>[Warnings and Precautions, Acute Tubulointerst...</td>\n",
       "      <td>[7 DRUG INTERACTIONS Tables 5 and 6 include dr...</td>\n",
       "      <td>[8.5 Geriatric Use In a clinical trial of pati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Antisecretory Activity ...</td>\n",
       "      <td>[11 DESCRIPTION The active ingredient in NEXIU...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS For Injection: 4...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.5 Pharmacogenomics CYP2C19, a polymorphic ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>20200312</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS A major step in roflumila...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 4438 COPD subjects e...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In COPD patients, 4‑wee...</td>\n",
       "      <td>[11 DESCRIPTION The active ingredient in DALIR...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS • DALIRESP 250 m...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Risk Summary There are no randomized clinical...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>20210730</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS No formal drug interactio...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 664 patients with SL...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In patients with SLE, f...</td>\n",
       "      <td>[11 DESCRIPTION Anifrolumab-fnia is a type I i...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Injection: 300 m...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>20190125</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[8.5 Geriatric Use In the combined safety data...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics The presence of moxetum...</td>\n",
       "      <td>[11 DESCRIPTION Moxetumomab pasudotox-tdfk is ...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS For injection: 1...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>20210223</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS No formal drug interactio...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of pati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In the 52-week Phase 2 ...</td>\n",
       "      <td>[11 DESCRIPTION Benralizumab is a humanized mo...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS FASENRA is a cle...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[&lt;table width=\"100%\"&gt;&lt;col width=\"56%\"/&gt;&lt;col wi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>20191122</td>\n",
       "      <td>[Indications and Usage (1.2) 11/2019 Dosage an...</td>\n",
       "      <td>[7 DRUG INTERACTIONS Strong CYP3A Inhibitors C...</td>\n",
       "      <td>[8.5 Geriatric Use Of the 929 patients with CL...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics In patients with B-cell...</td>\n",
       "      <td>[11 DESCRIPTION CALQUENCE (acalabrutinib) is a...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS 100 mg capsules....</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Risk Summary No data are available regarding ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>20201127</td>\n",
       "      <td>[Warnings and Precautions, Acute Tubulointerst...</td>\n",
       "      <td>[7 DRUG INTERACTIONS • May affect plasma level...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of pati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Antisecretory Activity ...</td>\n",
       "      <td>[11 DESCRIPTION The active ingredient in the p...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS NEXIUM Delayed-R...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>20200413</td>\n",
       "      <td>[Warnings and Precautions (5.3) 04/2020]</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Moderate CYP3A4 inhibit...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of subj...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Use of opioids induces ...</td>\n",
       "      <td>[11 DESCRIPTION MOVANTIK (naloxegol), an opioi...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS MOVANTIK (naloxe...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>20210217</td>\n",
       "      <td>[Indications and Usage (1.2) 05/2020 Indicatio...</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Avoid use with strong C...</td>\n",
       "      <td>[8.5 Geriatric Use About half of the patients ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics The inhibition of plate...</td>\n",
       "      <td>[11 DESCRIPTION BRILINTA contains ticagrelor, ...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS BRILINTA (ticagr...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[5.7 Laboratory Test Interferences False negat...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Decreased Platelet Aggregation [PE]]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>20190724</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS In clinical studies, conc...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of asth...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Asthma Cardiovascular e...</td>\n",
       "      <td>[11 DESCRIPTION SYMBICORT 80/4.5 and SYMBICORT...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>[&lt;table width=\"100%\"&gt; &lt;caption&gt;Table 1. Meta-a...</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS SYMBICORT is ava...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>20191024</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[7 DRUG INTERACTIONS • Coadministration with s...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Saxagliptin In patients...</td>\n",
       "      <td>[11 DESCRIPTION KOMBIGLYZE XR (saxagliptin and...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS • KOMBIGLYZE XR ...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Laboratory Tests Absolute Lymphocyte Counts S...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[Risk Summary Limited available data with KOMB...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>20180607</td>\n",
       "      <td>[Warnings and Precautions, Acute Tubulointerst...</td>\n",
       "      <td>[7 DRUG INTERACTIONS • May affect plasma level...</td>\n",
       "      <td>[8.5 Geriatric Use Of the total number of pati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[12.2 Pharmacodynamics Antisecretory Activity ...</td>\n",
       "      <td>[11 DESCRIPTION The active ingredient in the p...</td>\n",
       "      <td>[13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[3 DOSAGE FORMS AND STRENGTHS Esomeprazole mag...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>36 rows × 79 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   effective_time                               recent_major_changes  \\\n",
       "0        20200918        [Warnings and Precautions ( 5.20 ) 09/2020]   \n",
       "1        20201005                                                NaN   \n",
       "2        20190724                                                NaN   \n",
       "3        20210722  [Indications and Usage ( 1 ) 07/2021 Dosage an...   \n",
       "4        20191011                                                NaN   \n",
       "5        20200124  [Indications and Usage (1) 05/2019 Dosage and ...   \n",
       "6        20200918          [Warnings and Precautions (5.20) 09/2020]   \n",
       "7        20191218                                                NaN   \n",
       "8        20210617         [Warnings and Precautions (5.3) . 06/2021]   \n",
       "9        20191011                                                NaN   \n",
       "10       20210726  [Indications and Usage ( 1.1 ) 12/2020 Dosage ...   \n",
       "11       20200723                                                NaN   \n",
       "12       20210722  [Indications and Usage ( 1 ) 07/2021 Dosage an...   \n",
       "13       20210510  [Indications and Usage (1) 04/2021 Dosage and ...   \n",
       "14       20210610  [Indications and Usage (1) 05/2020 Dosage and ...   \n",
       "15       20210520                                                NaN   \n",
       "16       20210506                                                NaN   \n",
       "17       20200925                                                NaN   \n",
       "18       20210729  [Indications and Usage, Urothelial Carcinoma –...   \n",
       "19       20201022  [Dosage and Administration ( 2.2 ) 4/2020 Warn...   \n",
       "20       20200121  [Indications and Usage (1) 10/2019 Dosage and ...   \n",
       "21       20210223                                                NaN   \n",
       "22       20201105              [Indications and Usage ( 1 ) 11/2020]   \n",
       "23       20200925  [Dosage and Administration, Use with Concomita...   \n",
       "24       20201127  [Warnings and Precautions, Acute Tubulointerst...   \n",
       "25       20200312                                                NaN   \n",
       "26       20210730                                                NaN   \n",
       "27       20190125                                                NaN   \n",
       "28       20210223                                                NaN   \n",
       "29       20191122  [Indications and Usage (1.2) 11/2019 Dosage an...   \n",
       "30       20201127  [Warnings and Precautions, Acute Tubulointerst...   \n",
       "31       20200413           [Warnings and Precautions (5.3) 04/2020]   \n",
       "32       20210217  [Indications and Usage (1.2) 05/2020 Indicatio...   \n",
       "33       20190724                                                NaN   \n",
       "34       20191024                                                NaN   \n",
       "35       20180607  [Warnings and Precautions, Acute Tubulointerst...   \n",
       "\n",
       "                                    drug_interactions  \\\n",
       "0   [7 DRUG INTERACTIONS • Concomitant use of stro...   \n",
       "1   [7 DRUG INTERACTIONS There are no known drug-d...   \n",
       "2   [7 DRUG INTERACTIONS In clinical studies, conc...   \n",
       "3   [7 DRUG INTERACTIONS Table 3: Clinically Relev...   \n",
       "4   [7 DRUG INTERACTIONS Strong Cytochrome P450 3A...   \n",
       "5   [7 DRUG INTERACTIONS Table 2: Clinically Relev...   \n",
       "6   [7 DRUG INTERACTIONS • Concomitant use of stro...   \n",
       "7   [7 DRUG INTERACTIONS 7.1 Insulin The pharmacok...   \n",
       "8   [7 DRUG INTERACTIONS • May impact absorption o...   \n",
       "9   [7 DRUG INTERACTIONS • Strong Cytochrome P450 ...   \n",
       "10  [7 DRUG INTERACTIONS Strong CYP3A Inducers : A...   \n",
       "11  [7 DRUG INTERACTIONS No formal drug interactio...   \n",
       "12  [7 DRUG INTERACTIONS Table 4: Clinically Relev...   \n",
       "13  [7 DRUG INTERACTIONS 7.1 Positive Urine Glucos...   \n",
       "14  [7 DRUG INTERACTIONS • Strong or moderate CYP3...   \n",
       "15  [7 DRUG INTERACTIONS • Strong or Moderate CYP3...   \n",
       "16  [7 DRUG INTERACTIONS • CYP3A4 Inducer: Increas...   \n",
       "17  [7 DRUG INTERACTIONS There are no known drug-d...   \n",
       "18                                                NaN   \n",
       "19  [7 DRUG INTERACTIONS LOKELMA can transiently i...   \n",
       "20  [7 DRUG INTERACTIONS • Carbonic anhydrase inhi...   \n",
       "21  [7 DRUG INTERACTIONS In vitro studies suggest ...   \n",
       "22  [7 DRUG INTERACTIONS No formal drug interactio...   \n",
       "23  [7 DRUG INTERACTIONS • Combination of sofosbuv...   \n",
       "24  [7 DRUG INTERACTIONS Tables 5 and 6 include dr...   \n",
       "25  [7 DRUG INTERACTIONS A major step in roflumila...   \n",
       "26  [7 DRUG INTERACTIONS No formal drug interactio...   \n",
       "27                                                NaN   \n",
       "28  [7 DRUG INTERACTIONS No formal drug interactio...   \n",
       "29  [7 DRUG INTERACTIONS Strong CYP3A Inhibitors C...   \n",
       "30  [7 DRUG INTERACTIONS • May affect plasma level...   \n",
       "31  [7 DRUG INTERACTIONS • Moderate CYP3A4 inhibit...   \n",
       "32  [7 DRUG INTERACTIONS • Avoid use with strong C...   \n",
       "33  [7 DRUG INTERACTIONS In clinical studies, conc...   \n",
       "34  [7 DRUG INTERACTIONS • Coadministration with s...   \n",
       "35  [7 DRUG INTERACTIONS • May affect plasma level...   \n",
       "\n",
       "                                        geriatric_use  \\\n",
       "0   [8.5 Geriatric Use Of the approximately 3700 p...   \n",
       "1   [8.5 Geriatric Use For fulvestrant 250 mg, whe...   \n",
       "2   [8.5 Geriatric Use Of the total number of asth...   \n",
       "3   [8.5 Geriatric Use In two comparator-controlle...   \n",
       "4   [8.5 Geriatric Use Of the 215 patients in 3 cl...   \n",
       "5   [8.5 Geriatric Use Because elderly patients ar...   \n",
       "6   [8.5 Geriatric Use Sixty-eight patients in cli...   \n",
       "7   [8.5 Geriatric Use SYMLIN has been studied in ...   \n",
       "8   [8.5 Geriatric Use Population pharmacokinetic ...   \n",
       "9   [8.5 Geriatric Use Of the total number of pati...   \n",
       "10  [8.5 Geriatric Use Forty-three percent (43%) o...   \n",
       "11  [8.5 Geriatric Use Based on available data, no...   \n",
       "12  [8.5 Geriatric Use In five comparator-controll...   \n",
       "13  [8.5 Geriatric Use No FARXIGA dosage change is...   \n",
       "14  [8.5 Geriatric Use Of the 2351 patients with a...   \n",
       "15  [8.5 Geriatric Use Clinical studies did not in...   \n",
       "16  [8.5 Geriatric Use Of the 823 patients enrolle...   \n",
       "17  [8.5 Geriatric Use For FASLODEX 250 mg, when t...   \n",
       "18  [8.5 Geriatric Use Of the 476 patients treated...   \n",
       "19  [8.5 Geriatric Use Of the total number of subj...   \n",
       "20  [8.5 Geriatric Use XIGDUO XR No XIGDUO XR dosa...   \n",
       "21  [8.5 Geriatric Use Of the 636 COPD patients ex...   \n",
       "22  [8.5 Geriatric Use Based on available data, no...   \n",
       "23  [8.5 Geriatric Use Of the 10,275 patients in c...   \n",
       "24  [8.5 Geriatric Use In a clinical trial of pati...   \n",
       "25  [8.5 Geriatric Use Of the 4438 COPD subjects e...   \n",
       "26  [8.5 Geriatric Use Of the 664 patients with SL...   \n",
       "27  [8.5 Geriatric Use In the combined safety data...   \n",
       "28  [8.5 Geriatric Use Of the total number of pati...   \n",
       "29  [8.5 Geriatric Use Of the 929 patients with CL...   \n",
       "30  [8.5 Geriatric Use Of the total number of pati...   \n",
       "31  [8.5 Geriatric Use Of the total number of subj...   \n",
       "32  [8.5 Geriatric Use About half of the patients ...   \n",
       "33  [8.5 Geriatric Use Of the total number of asth...   \n",
       "34                                                NaN   \n",
       "35  [8.5 Geriatric Use Of the total number of pati...   \n",
       "\n",
       "                                                abuse  \\\n",
       "0   [9.2 Abuse SEROQUEL has not been systematicall...   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6   [9.2 Abuse SEROQUEL XR has not been systematic...   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                                     pharmacodynamics  \\\n",
       "0   [12.2 Pharmacodynamics Quetiapine and its meta...   \n",
       "1   [12.2 Pharmacodynamics In a clinical study in ...   \n",
       "2   [12.2 Pharmacodynamics Asthma Cardiovascular e...   \n",
       "3   [12.2 Pharmacodynamics Exenatide improves glyc...   \n",
       "4   [12.2 Pharmacodynamics The therapeutic effects...   \n",
       "5   [12.2 Pharmacodynamics Dapagliflozin Increases...   \n",
       "6   [12.2 Pharmacodynamics Quetiapine and its meta...   \n",
       "7   [12.2 Pharmacodynamics In clinical studies in ...   \n",
       "8   [12.2 Pharmacodynamics Glucose-Dependent Insul...   \n",
       "9   [12.2 Pharmacodynamics To confirm that systemi...   \n",
       "10  [12.2 Pharmacodynamics Based on an analysis of...   \n",
       "11  [12.2 Pharmacodynamics Cardiac Electrophysiolo...   \n",
       "12  [12.2 Pharmacodynamics Exenatide improves glyc...   \n",
       "13  [12.2 Pharmacodynamics General Increases in th...   \n",
       "14                                                NaN   \n",
       "15  [12.2 Pharmacodynamics The exposure-response r...   \n",
       "16                                                NaN   \n",
       "17  [12.2 Pharmacodynamics In a clinical study in ...   \n",
       "18  [12.2 Pharmacodynamics The steady state AUC, C...   \n",
       "19  [12.2 Pharmacodynamics In a study in healthy a...   \n",
       "20  [12.2 Pharmacodynamics General Dapagliflozin I...   \n",
       "21  [12.2 Pharmacodynamics Cardiovascular Effects ...   \n",
       "22  [12.2 Pharmacodynamics Cardiac Electrophysiolo...   \n",
       "23  [12.2 Pharmacodynamics CRESTOR dose dependentl...   \n",
       "24  [12.2 Pharmacodynamics Antisecretory Activity ...   \n",
       "25  [12.2 Pharmacodynamics In COPD patients, 4‑wee...   \n",
       "26  [12.2 Pharmacodynamics In patients with SLE, f...   \n",
       "27  [12.2 Pharmacodynamics The presence of moxetum...   \n",
       "28  [12.2 Pharmacodynamics In the 52-week Phase 2 ...   \n",
       "29  [12.2 Pharmacodynamics In patients with B-cell...   \n",
       "30  [12.2 Pharmacodynamics Antisecretory Activity ...   \n",
       "31  [12.2 Pharmacodynamics Use of opioids induces ...   \n",
       "32  [12.2 Pharmacodynamics The inhibition of plate...   \n",
       "33  [12.2 Pharmacodynamics Asthma Cardiovascular e...   \n",
       "34  [12.2 Pharmacodynamics Saxagliptin In patients...   \n",
       "35  [12.2 Pharmacodynamics Antisecretory Activity ...   \n",
       "\n",
       "                                          description  \\\n",
       "0   [11 DESCRIPTION SEROQUEL ® (quetiapine) is an ...   \n",
       "1   [11 DESCRIPTION FULVESTRANT INJECTION for intr...   \n",
       "2   [11 DESCRIPTION BUDESONIDE AND FORMOTEROL FUMA...   \n",
       "3   [11 DESCRIPTION BYDUREON BCISE (exenatide exte...   \n",
       "4   [11 DESCRIPTION Budesonide, the active compone...   \n",
       "5   [11 DESCRIPTION QTERN tablets for oral use con...   \n",
       "6   [11 DESCRIPTION SEROQUEL XR (quetiapine) is an...   \n",
       "7   [11 DESCRIPTION SYMLIN ® (pramlintide acetate)...   \n",
       "8   [11 DESCRIPTION BYETTA (exenatide) is a synthe...   \n",
       "9   [11 DESCRIPTION Budesonide, the active compone...   \n",
       "10  [11 DESCRIPTION Osimertinib is a kinase inhibi...   \n",
       "11  [11 DESCRIPTION BREZTRI AEROSPHERE (budesonide...   \n",
       "12  [11 DESCRIPTION BYDUREON (exenatide extended-r...   \n",
       "13  [11 DESCRIPTION Dapagliflozin is described che...   \n",
       "14  [11 DESCRIPTION Olaparib is a poly (ADP-ribose...   \n",
       "15  [11 DESCRIPTION Selumetinib is a kinase inhibi...   \n",
       "16  [11 DESCRIPTION Gefitinib is a kinase inhibito...   \n",
       "17  [11 DESCRIPTION FASLODEX ® (fulvestrant) injec...   \n",
       "18  [11 DESCRIPTION Durvalumab is a programmed cel...   \n",
       "19  [11 DESCRIPTION LOKELMA is a powder for oral s...   \n",
       "20  [11 DESCRIPTION XIGDUO XR (dapagliflozin and m...   \n",
       "21  [11 DESCRIPTION TUDORZA PRESSAIR consists of a...   \n",
       "22  [11 DESCRIPTION BEVESPI AEROSPHERE (glycopyrro...   \n",
       "23  [11 DESCRIPTION CRESTOR (rosuvastatin calcium)...   \n",
       "24  [11 DESCRIPTION The active ingredient in NEXIU...   \n",
       "25  [11 DESCRIPTION The active ingredient in DALIR...   \n",
       "26  [11 DESCRIPTION Anifrolumab-fnia is a type I i...   \n",
       "27  [11 DESCRIPTION Moxetumomab pasudotox-tdfk is ...   \n",
       "28  [11 DESCRIPTION Benralizumab is a humanized mo...   \n",
       "29  [11 DESCRIPTION CALQUENCE (acalabrutinib) is a...   \n",
       "30  [11 DESCRIPTION The active ingredient in the p...   \n",
       "31  [11 DESCRIPTION MOVANTIK (naloxegol), an opioi...   \n",
       "32  [11 DESCRIPTION BRILINTA contains ticagrelor, ...   \n",
       "33  [11 DESCRIPTION SYMBICORT 80/4.5 and SYMBICORT...   \n",
       "34  [11 DESCRIPTION KOMBIGLYZE XR (saxagliptin and...   \n",
       "35  [11 DESCRIPTION The active ingredient in the p...   \n",
       "\n",
       "                               nonclinical_toxicology  \\\n",
       "0   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "1   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "2   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "3   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "4   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "5   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "6   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "7   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "8   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "9   [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "10  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "11  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "12  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "13  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "14  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "15  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "16  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "17  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "18  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "19  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "20  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "21  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "22  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "23  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "24  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "25  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "26  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "27  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "28  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "29  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "30  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "31  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "32  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "33  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "34  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "35  [13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis...   \n",
       "\n",
       "                          warnings_and_cautions_table  \\\n",
       "0   [<table width=\"100%\"><caption>Table 2: Drug-Pl...   \n",
       "1                                                 NaN   \n",
       "2   [<table ID=\"_RefID0EKJAE\" width=\"100%\"> <capti...   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6   [<table width=\"100%\"><caption>Table 2: Drug-Pl...   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  [<table width=\"100%\"> <caption>Table 1. Meta-a...   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                           dosage_forms_and_strengths  ...  \\\n",
       "0   [3 DOSAGE FORMS AND STRENGTHS • 25 mg tablets ...  ...   \n",
       "1   [3 DOSAGE FORMS AND STRENGTHS FULVESTRANT INJE...  ...   \n",
       "2   [3 DOSAGE FORMS AND STRENGTHS BUDESONIDE AND F...  ...   \n",
       "3   [3 DOSAGE FORMS AND STRENGTHS Extended-release...  ...   \n",
       "4   [3 DOSAGE FORMS AND STRENGTHS PULMICORT RESPUL...  ...   \n",
       "5   [3 DOSAGE FORMS AND STRENGTHS Tablets: • 5 mg ...  ...   \n",
       "6   [3 DOSAGE FORMS AND STRENGTHS • 50 mg extended...  ...   \n",
       "7   [3 DOSAGE FORMS AND STRENGTHS SYMLIN is suppli...  ...   \n",
       "8   [3 DOSAGE FORMS AND STRENGTHS BYETTA injection...  ...   \n",
       "9   [3 DOSAGE FORMS AND STRENGTHS PULMICORT FLEXHA...  ...   \n",
       "10  [3 DOSAGE FORMS AND STRENGTHS 80 mg tablets: b...  ...   \n",
       "11  [3 DOSAGE FORMS AND STRENGTHS Inhalation Aeros...  ...   \n",
       "12  [3 DOSAGE FORMS AND STRENGTHS Extended-release...  ...   \n",
       "13  [3 DOSAGE FORMS AND STRENGTHS • FARXIGA 5 mg t...  ...   \n",
       "14  [3 DOSAGE FORMS AND STRENGTHS Tablets: • 150 m...  ...   \n",
       "15  [3 DOSAGE FORMS AND STRENGTHS Capsules: • 10 m...  ...   \n",
       "16  [3 DOSAGE FORMS AND STRENGTHS 250 mg tablets: ...  ...   \n",
       "17  [3 DOSAGE FORMS AND STRENGTHS FASLODEX, an inj...  ...   \n",
       "18  [3 DOSAGE FORMS AND STRENGTHS Injection: 120 m...  ...   \n",
       "19  [3 DOSAGE FORMS AND STRENGTHS For oral suspens...  ...   \n",
       "20  [3 DOSAGE FORMS AND STRENGTHS XIGDUO XR (dapag...  ...   \n",
       "21  [3 DOSAGE FORMS AND STRENGTHS Inhalation Powde...  ...   \n",
       "22  [3 DOSAGE FORMS AND STRENGTHS Inhalation aeros...  ...   \n",
       "23  [3 DOSAGE FORMS AND STRENGTHS 5 mg: Yellow, ro...  ...   \n",
       "24  [3 DOSAGE FORMS AND STRENGTHS For Injection: 4...  ...   \n",
       "25  [3 DOSAGE FORMS AND STRENGTHS • DALIRESP 250 m...  ...   \n",
       "26  [3 DOSAGE FORMS AND STRENGTHS Injection: 300 m...  ...   \n",
       "27  [3 DOSAGE FORMS AND STRENGTHS For injection: 1...  ...   \n",
       "28  [3 DOSAGE FORMS AND STRENGTHS FASENRA is a cle...  ...   \n",
       "29  [3 DOSAGE FORMS AND STRENGTHS 100 mg capsules....  ...   \n",
       "30  [3 DOSAGE FORMS AND STRENGTHS NEXIUM Delayed-R...  ...   \n",
       "31  [3 DOSAGE FORMS AND STRENGTHS MOVANTIK (naloxe...  ...   \n",
       "32  [3 DOSAGE FORMS AND STRENGTHS BRILINTA (ticagr...  ...   \n",
       "33  [3 DOSAGE FORMS AND STRENGTHS SYMBICORT is ava...  ...   \n",
       "34  [3 DOSAGE FORMS AND STRENGTHS • KOMBIGLYZE XR ...  ...   \n",
       "35  [3 DOSAGE FORMS AND STRENGTHS Esomeprazole mag...  ...   \n",
       "\n",
       "                           storage_and_handling_table  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7   [<table ID=\"_Reftable9\" width=\"100%\"> <caption...   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                       patient_medication_information  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11  [PATIENT INFORMATION BREZTRI AEROSPHERE™ (brez...   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                 patient_medication_information_table  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11  [<table width=\"100%\"><col width=\"50%\"/><col wi...   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                                                risks  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11  [Risk Summary There are no adequate and well-c...   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29  [Risk Summary No data are available regarding ...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                             spl_unclassified_section  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13  [Distributed by: AstraZeneca Pharmaceuticals L...   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "          package_label_principal_display_panel_table  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17  [<table width=\"100%\"><col width=\"39%\"/><col wi...   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28  [<table width=\"100%\"><col width=\"56%\"/><col wi...   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                                     laboratory_tests  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20  [Laboratory Tests Increases in Serum Creatinin...   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32  [5.7 Laboratory Test Interferences False negat...   \n",
       "33                                                NaN   \n",
       "34  [Laboratory Tests Absolute Lymphocyte Counts S...   \n",
       "35                                                NaN   \n",
       "\n",
       "                                     pharmacogenomics  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24  [12.5 Pharmacogenomics CYP2C19, a polymorphic ...   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "\n",
       "                                  teratogenic_effects  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25  [Risk Summary There are no randomized clinical...   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34  [Risk Summary Limited available data with KOMB...   \n",
       "35                                                NaN   \n",
       "\n",
       "                   openfda.pharm_class_pe  \n",
       "0                                     NaN  \n",
       "1                                     NaN  \n",
       "2                                     NaN  \n",
       "3                                     NaN  \n",
       "4                                     NaN  \n",
       "5                                     NaN  \n",
       "6                                     NaN  \n",
       "7                                     NaN  \n",
       "8                                     NaN  \n",
       "9                                     NaN  \n",
       "10                                    NaN  \n",
       "11                                    NaN  \n",
       "12                                    NaN  \n",
       "13                                    NaN  \n",
       "14                                    NaN  \n",
       "15                                    NaN  \n",
       "16                                    NaN  \n",
       "17                                    NaN  \n",
       "18                                    NaN  \n",
       "19                                    NaN  \n",
       "20                                    NaN  \n",
       "21                                    NaN  \n",
       "22                                    NaN  \n",
       "23                                    NaN  \n",
       "24                                    NaN  \n",
       "25                                    NaN  \n",
       "26                                    NaN  \n",
       "27                                    NaN  \n",
       "28                                    NaN  \n",
       "29                                    NaN  \n",
       "30                                    NaN  \n",
       "31                                    NaN  \n",
       "32  [Decreased Platelet Aggregation [PE]]  \n",
       "33                                    NaN  \n",
       "34                                    NaN  \n",
       "35                                    NaN  \n",
       "\n",
       "[36 rows x 79 columns]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     20200918\n",
       "1     20201005\n",
       "2     20190724\n",
       "3     20210722\n",
       "4     20191011\n",
       "5     20200124\n",
       "6     20200918\n",
       "7     20191218\n",
       "8     20210617\n",
       "9     20191011\n",
       "10    20210726\n",
       "11    20200723\n",
       "12    20210722\n",
       "13    20210510\n",
       "14    20210610\n",
       "15    20210520\n",
       "16    20210506\n",
       "17    20200925\n",
       "18    20210729\n",
       "19    20201022\n",
       "20    20200121\n",
       "21    20210223\n",
       "22    20201105\n",
       "23    20200925\n",
       "24    20201127\n",
       "25    20200312\n",
       "26    20210730\n",
       "27    20190125\n",
       "28    20210223\n",
       "29    20191122\n",
       "30    20201127\n",
       "31    20200413\n",
       "32    20210217\n",
       "33    20190724\n",
       "34    20191024\n",
       "35    20180607\n",
       "Name: effective_time, dtype: object"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n['effective_time']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "####Extracting only year from the date############\n",
    "js_n['year'] = pd.DatetimeIndex(js_n['effective_time']).year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     2020\n",
       "1     2020\n",
       "2     2019\n",
       "3     2021\n",
       "4     2019\n",
       "5     2020\n",
       "6     2020\n",
       "7     2019\n",
       "8     2021\n",
       "9     2019\n",
       "10    2021\n",
       "11    2020\n",
       "12    2021\n",
       "13    2021\n",
       "14    2021\n",
       "15    2021\n",
       "16    2021\n",
       "17    2020\n",
       "18    2021\n",
       "19    2020\n",
       "20    2020\n",
       "21    2021\n",
       "22    2020\n",
       "23    2020\n",
       "24    2020\n",
       "25    2020\n",
       "26    2021\n",
       "27    2019\n",
       "28    2021\n",
       "29    2019\n",
       "30    2020\n",
       "31    2020\n",
       "32    2021\n",
       "33    2019\n",
       "34    2019\n",
       "35    2018\n",
       "Name: year, dtype: int64"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n[\"year\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>year</th>\n",
       "      <th>spl_product_data_elements</th>\n",
       "      <th>openfda.generic_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2020</td>\n",
       "      <td>[SEROQUEL quetiapine QUETIAPINE FUMARATE QUETI...</td>\n",
       "      <td>[QUETIAPINE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2020</td>\n",
       "      <td>[Fulvestrant Fulvestrant FULVESTRANT FULVESTRA...</td>\n",
       "      <td>[FULVESTRANT]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2019</td>\n",
       "      <td>[Budesonide and Formoterol Fumarate Dihydrate ...</td>\n",
       "      <td>[BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2021</td>\n",
       "      <td>[BYDUREON BCise exenatide EXENATIDE EXENATIDE ...</td>\n",
       "      <td>[EXENATIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2019</td>\n",
       "      <td>[PULMICORT RESPULES Budesonide BUDESONIDE BUDE...</td>\n",
       "      <td>[BUDESONIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>2020</td>\n",
       "      <td>[QTERN dapagliflozin and saxagliptin DAPAGLIFL...</td>\n",
       "      <td>[DAPAGLIFLOZIN AND SAXAGLIPTIN]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2020</td>\n",
       "      <td>[SEROQUEL XR quetiapine QUETIAPINE FUMARATE QU...</td>\n",
       "      <td>[QUETIAPINE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>2019</td>\n",
       "      <td>[SymlinPen pramlintide acetate pramlintide ace...</td>\n",
       "      <td>[PRAMLINTIDE ACETATE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2021</td>\n",
       "      <td>[Byetta exenatide exenatide exenatide metacres...</td>\n",
       "      <td>[EXENATIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2019</td>\n",
       "      <td>[PULMICORT FLEXHALER Budesonide BUDESONIDE BUD...</td>\n",
       "      <td>[BUDESONIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>2021</td>\n",
       "      <td>[TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB ...</td>\n",
       "      <td>[OSIMERTINIB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2020</td>\n",
       "      <td>[BREZTRI budesonide, glycopyrrolate, and formo...</td>\n",
       "      <td>[BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FU...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2021</td>\n",
       "      <td>[BYDUREON exenatide EXENATIDE EXENATIDE POLY(D...</td>\n",
       "      <td>[EXENATIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2021</td>\n",
       "      <td>[FARXIGA DAPAGLIFLOZIN DAPAGLIFLOZIN PROPANEDI...</td>\n",
       "      <td>[DAPAGLIFLOZIN]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2021</td>\n",
       "      <td>[Lynparza olaparib OLAPARIB OLAPARIB HYPROMELL...</td>\n",
       "      <td>[OLAPARIB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>2021</td>\n",
       "      <td>[KOSELUGO SELUMETINIB SELUMETINIB SELUMETINIB ...</td>\n",
       "      <td>[SELUMETINIB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>2021</td>\n",
       "      <td>[IRESSA Gefitinib GEFITINIB GEFITINIB LACTOSE ...</td>\n",
       "      <td>[GEFITINIB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>2020</td>\n",
       "      <td>[FASLODEX Fulvestrant FULVESTRANT FULVESTRANT ...</td>\n",
       "      <td>[FULVESTRANT]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>2021</td>\n",
       "      <td>[IMFINZI Durvalumab DURVALUMAB DURVALUMAB HIST...</td>\n",
       "      <td>[DURVALUMAB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2020</td>\n",
       "      <td>[LOKELMA sodium zirconium cyclosilicate SODIUM...</td>\n",
       "      <td>[SODIUM ZIRCONIUM CYCLOSILICATE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>2020</td>\n",
       "      <td>[XIGDUO XR dapagliflozin and metformin hydroch...</td>\n",
       "      <td>[DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>2021</td>\n",
       "      <td>[Tudorza Pressair aclidinium bromide ACLIDINIU...</td>\n",
       "      <td>[ACLIDINIUM BROMIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>2020</td>\n",
       "      <td>[BEVESPI AEROSPHERE Glycopyrrolate and formote...</td>\n",
       "      <td>[GLYCOPYRROLATE AND FORMOTEROL FUMARATE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>2020</td>\n",
       "      <td>[CRESTOR Rosuvastatin calcium ROSUVASTATIN CAL...</td>\n",
       "      <td>[ROSUVASTATIN CALCIUM]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>2020</td>\n",
       "      <td>[NEXIUM I.V. Esomeprazole sodium ESOMEPRAZOLE ...</td>\n",
       "      <td>[ESOMEPRAZOLE SODIUM]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>2020</td>\n",
       "      <td>[Daliresp roflumilast roflumilast roflumilast ...</td>\n",
       "      <td>[ROFLUMILAST]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>2021</td>\n",
       "      <td>[SAPHNELO Anifrolumab ANIFROLUMAB ANIFROLUMAB ...</td>\n",
       "      <td>[ANIFROLUMAB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>2019</td>\n",
       "      <td>[LUMOXITI moxetumomab pasudotox MOXETUMOMAB PA...</td>\n",
       "      <td>[MOXETUMOMAB PASUDOTOX]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>2021</td>\n",
       "      <td>[FASENRA Benralizumab BENRALIZUMAB BENRALIZUMA...</td>\n",
       "      <td>[BENRALIZUMAB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>2019</td>\n",
       "      <td>[CALQUENCE Acalabrutinib ACALABRUTINIB ACALABR...</td>\n",
       "      <td>[ACALABRUTINIB]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>2020</td>\n",
       "      <td>[NEXIUM Esomeprazole magnesium ESOMEPRAZOLE MA...</td>\n",
       "      <td>[ESOMEPRAZOLE MAGNESIUM]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>2020</td>\n",
       "      <td>[MOVANTIK naloxegol oxalate NALOXEGOL OXALATE ...</td>\n",
       "      <td>[NALOXEGOL OXALATE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>2021</td>\n",
       "      <td>[BRILINTA Ticagrelor TICAGRELOR TICAGRELOR MAN...</td>\n",
       "      <td>[TICAGRELOR]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>2019</td>\n",
       "      <td>[SYMBICORT Budesonide and Formoterol Fumarate ...</td>\n",
       "      <td>[BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>2019</td>\n",
       "      <td>[KOMBIGLYZE XR SAXAGLIPTIN AND METFORMIN HYDRO...</td>\n",
       "      <td>[SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>2018</td>\n",
       "      <td>[Esomeprazole magnesium Esomeprazole magnesium...</td>\n",
       "      <td>[ESOMEPRAZOLE MAGNESIUM]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    year                          spl_product_data_elements  \\\n",
       "0   2020  [SEROQUEL quetiapine QUETIAPINE FUMARATE QUETI...   \n",
       "1   2020  [Fulvestrant Fulvestrant FULVESTRANT FULVESTRA...   \n",
       "2   2019  [Budesonide and Formoterol Fumarate Dihydrate ...   \n",
       "3   2021  [BYDUREON BCise exenatide EXENATIDE EXENATIDE ...   \n",
       "4   2019  [PULMICORT RESPULES Budesonide BUDESONIDE BUDE...   \n",
       "5   2020  [QTERN dapagliflozin and saxagliptin DAPAGLIFL...   \n",
       "6   2020  [SEROQUEL XR quetiapine QUETIAPINE FUMARATE QU...   \n",
       "7   2019  [SymlinPen pramlintide acetate pramlintide ace...   \n",
       "8   2021  [Byetta exenatide exenatide exenatide metacres...   \n",
       "9   2019  [PULMICORT FLEXHALER Budesonide BUDESONIDE BUD...   \n",
       "10  2021  [TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB ...   \n",
       "11  2020  [BREZTRI budesonide, glycopyrrolate, and formo...   \n",
       "12  2021  [BYDUREON exenatide EXENATIDE EXENATIDE POLY(D...   \n",
       "13  2021  [FARXIGA DAPAGLIFLOZIN DAPAGLIFLOZIN PROPANEDI...   \n",
       "14  2021  [Lynparza olaparib OLAPARIB OLAPARIB HYPROMELL...   \n",
       "15  2021  [KOSELUGO SELUMETINIB SELUMETINIB SELUMETINIB ...   \n",
       "16  2021  [IRESSA Gefitinib GEFITINIB GEFITINIB LACTOSE ...   \n",
       "17  2020  [FASLODEX Fulvestrant FULVESTRANT FULVESTRANT ...   \n",
       "18  2021  [IMFINZI Durvalumab DURVALUMAB DURVALUMAB HIST...   \n",
       "19  2020  [LOKELMA sodium zirconium cyclosilicate SODIUM...   \n",
       "20  2020  [XIGDUO XR dapagliflozin and metformin hydroch...   \n",
       "21  2021  [Tudorza Pressair aclidinium bromide ACLIDINIU...   \n",
       "22  2020  [BEVESPI AEROSPHERE Glycopyrrolate and formote...   \n",
       "23  2020  [CRESTOR Rosuvastatin calcium ROSUVASTATIN CAL...   \n",
       "24  2020  [NEXIUM I.V. Esomeprazole sodium ESOMEPRAZOLE ...   \n",
       "25  2020  [Daliresp roflumilast roflumilast roflumilast ...   \n",
       "26  2021  [SAPHNELO Anifrolumab ANIFROLUMAB ANIFROLUMAB ...   \n",
       "27  2019  [LUMOXITI moxetumomab pasudotox MOXETUMOMAB PA...   \n",
       "28  2021  [FASENRA Benralizumab BENRALIZUMAB BENRALIZUMA...   \n",
       "29  2019  [CALQUENCE Acalabrutinib ACALABRUTINIB ACALABR...   \n",
       "30  2020  [NEXIUM Esomeprazole magnesium ESOMEPRAZOLE MA...   \n",
       "31  2020  [MOVANTIK naloxegol oxalate NALOXEGOL OXALATE ...   \n",
       "32  2021  [BRILINTA Ticagrelor TICAGRELOR TICAGRELOR MAN...   \n",
       "33  2019  [SYMBICORT Budesonide and Formoterol Fumarate ...   \n",
       "34  2019  [KOMBIGLYZE XR SAXAGLIPTIN AND METFORMIN HYDRO...   \n",
       "35  2018  [Esomeprazole magnesium Esomeprazole magnesium...   \n",
       "\n",
       "                                 openfda.generic_name  \n",
       "0                                        [QUETIAPINE]  \n",
       "1                                       [FULVESTRANT]  \n",
       "2      [BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]  \n",
       "3                                         [EXENATIDE]  \n",
       "4                                        [BUDESONIDE]  \n",
       "5                     [DAPAGLIFLOZIN AND SAXAGLIPTIN]  \n",
       "6                                        [QUETIAPINE]  \n",
       "7                               [PRAMLINTIDE ACETATE]  \n",
       "8                                         [EXENATIDE]  \n",
       "9                                        [BUDESONIDE]  \n",
       "10                                      [OSIMERTINIB]  \n",
       "11  [BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FU...  \n",
       "12                                        [EXENATIDE]  \n",
       "13                                    [DAPAGLIFLOZIN]  \n",
       "14                                         [OLAPARIB]  \n",
       "15                                      [SELUMETINIB]  \n",
       "16                                        [GEFITINIB]  \n",
       "17                                      [FULVESTRANT]  \n",
       "18                                       [DURVALUMAB]  \n",
       "19                   [SODIUM ZIRCONIUM CYCLOSILICATE]  \n",
       "20        [DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE]  \n",
       "21                               [ACLIDINIUM BROMIDE]  \n",
       "22           [GLYCOPYRROLATE AND FORMOTEROL FUMARATE]  \n",
       "23                             [ROSUVASTATIN CALCIUM]  \n",
       "24                              [ESOMEPRAZOLE SODIUM]  \n",
       "25                                      [ROFLUMILAST]  \n",
       "26                                      [ANIFROLUMAB]  \n",
       "27                            [MOXETUMOMAB PASUDOTOX]  \n",
       "28                                     [BENRALIZUMAB]  \n",
       "29                                    [ACALABRUTINIB]  \n",
       "30                           [ESOMEPRAZOLE MAGNESIUM]  \n",
       "31                                [NALOXEGOL OXALATE]  \n",
       "32                                       [TICAGRELOR]  \n",
       "33     [BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]  \n",
       "34          [SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE]  \n",
       "35                           [ESOMEPRAZOLE MAGNESIUM]  "
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n[[\"year\",\"spl_product_data_elements\",\"openfda.generic_name\"]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['SEROQUEL quetiapine QUETIAPINE FUMARATE QUETIAPINE POVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE FERRIC OXIDE RED FERRIC OXIDE YELLOW LACTOSE MONOHYDRATE WATER peach biconvex SEROQUEL;25 SEROQUEL quetiapine QUETIAPINE FUMARATE QUETIAPINE POVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE LACTOSE MONOHYDRATE WATER FERRIC OXIDE YELLOW biconvex SEROQUEL;50 SEROQUEL quetiapine QUETIAPINE FUMARATE QUETIAPINE POVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE FERRIC OXIDE YELLOW WATER biconvex SEROQUEL;100 SEROQUEL quetiapine QUETIAPINE FUMARATE QUETIAPINE POVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE WATER biconvex SEROQUEL;200 SEROQUEL quetiapine QUETIAPINE FUMARATE QUETIAPINE POVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE WATER biconvex SEROQUEL;300 SEROQUEL quetiapine QUETIAPINE FUMARATE QUETIAPINE POVIDONE, UNSPECIFIED DIBASIC CALCIUM PHOSPHATE DIHYDRATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO LACTOSE MONOHYDRATE MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE FERRIC OXIDE YELLOW WATER biconvex SEROQUEL;400']"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n[\"spl_product_data_elements\"][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "pandas.core.series.Series"
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(js_n[\"openfda.generic_name\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "#####counting the ingredients############\n",
    "js_n['number_of_ingredients'] = js_n['spl_product_data_elements'].apply(lambda x: len(x[0].split(',')))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>year</th>\n",
       "      <th>spl_product_data_elements</th>\n",
       "      <th>openfda.generic_name</th>\n",
       "      <th>number_of_ingredients</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2020</td>\n",
       "      <td>[SEROQUEL quetiapine QUETIAPINE FUMARATE QUETI...</td>\n",
       "      <td>[QUETIAPINE]</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2020</td>\n",
       "      <td>[Fulvestrant Fulvestrant FULVESTRANT FULVESTRA...</td>\n",
       "      <td>[FULVESTRANT]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2019</td>\n",
       "      <td>[Budesonide and Formoterol Fumarate Dihydrate ...</td>\n",
       "      <td>[BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2021</td>\n",
       "      <td>[BYDUREON BCise exenatide EXENATIDE EXENATIDE ...</td>\n",
       "      <td>[EXENATIDE]</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2019</td>\n",
       "      <td>[PULMICORT RESPULES Budesonide BUDESONIDE BUDE...</td>\n",
       "      <td>[BUDESONIDE]</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>2020</td>\n",
       "      <td>[QTERN dapagliflozin and saxagliptin DAPAGLIFL...</td>\n",
       "      <td>[DAPAGLIFLOZIN AND SAXAGLIPTIN]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2020</td>\n",
       "      <td>[SEROQUEL XR quetiapine QUETIAPINE FUMARATE QU...</td>\n",
       "      <td>[QUETIAPINE]</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>2019</td>\n",
       "      <td>[SymlinPen pramlintide acetate pramlintide ace...</td>\n",
       "      <td>[PRAMLINTIDE ACETATE]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2021</td>\n",
       "      <td>[Byetta exenatide exenatide exenatide metacres...</td>\n",
       "      <td>[EXENATIDE]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2019</td>\n",
       "      <td>[PULMICORT FLEXHALER Budesonide BUDESONIDE BUD...</td>\n",
       "      <td>[BUDESONIDE]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>2021</td>\n",
       "      <td>[TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB ...</td>\n",
       "      <td>[OSIMERTINIB]</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2020</td>\n",
       "      <td>[BREZTRI budesonide, glycopyrrolate, and formo...</td>\n",
       "      <td>[BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FU...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2021</td>\n",
       "      <td>[BYDUREON exenatide EXENATIDE EXENATIDE POLY(D...</td>\n",
       "      <td>[EXENATIDE]</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2021</td>\n",
       "      <td>[FARXIGA DAPAGLIFLOZIN DAPAGLIFLOZIN PROPANEDI...</td>\n",
       "      <td>[DAPAGLIFLOZIN]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2021</td>\n",
       "      <td>[Lynparza olaparib OLAPARIB OLAPARIB HYPROMELL...</td>\n",
       "      <td>[OLAPARIB]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>2021</td>\n",
       "      <td>[KOSELUGO SELUMETINIB SELUMETINIB SELUMETINIB ...</td>\n",
       "      <td>[SELUMETINIB]</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>2021</td>\n",
       "      <td>[IRESSA Gefitinib GEFITINIB GEFITINIB LACTOSE ...</td>\n",
       "      <td>[GEFITINIB]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>2020</td>\n",
       "      <td>[FASLODEX Fulvestrant FULVESTRANT FULVESTRANT ...</td>\n",
       "      <td>[FULVESTRANT]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>2021</td>\n",
       "      <td>[IMFINZI Durvalumab DURVALUMAB DURVALUMAB HIST...</td>\n",
       "      <td>[DURVALUMAB]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2020</td>\n",
       "      <td>[LOKELMA sodium zirconium cyclosilicate SODIUM...</td>\n",
       "      <td>[SODIUM ZIRCONIUM CYCLOSILICATE]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>2020</td>\n",
       "      <td>[XIGDUO XR dapagliflozin and metformin hydroch...</td>\n",
       "      <td>[DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE]</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>2021</td>\n",
       "      <td>[Tudorza Pressair aclidinium bromide ACLIDINIU...</td>\n",
       "      <td>[ACLIDINIUM BROMIDE]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>2020</td>\n",
       "      <td>[BEVESPI AEROSPHERE Glycopyrrolate and formote...</td>\n",
       "      <td>[GLYCOPYRROLATE AND FORMOTEROL FUMARATE]</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>2020</td>\n",
       "      <td>[CRESTOR Rosuvastatin calcium ROSUVASTATIN CAL...</td>\n",
       "      <td>[ROSUVASTATIN CALCIUM]</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>2020</td>\n",
       "      <td>[NEXIUM I.V. Esomeprazole sodium ESOMEPRAZOLE ...</td>\n",
       "      <td>[ESOMEPRAZOLE SODIUM]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>2020</td>\n",
       "      <td>[Daliresp roflumilast roflumilast roflumilast ...</td>\n",
       "      <td>[ROFLUMILAST]</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>2021</td>\n",
       "      <td>[SAPHNELO Anifrolumab ANIFROLUMAB ANIFROLUMAB ...</td>\n",
       "      <td>[ANIFROLUMAB]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>2019</td>\n",
       "      <td>[LUMOXITI moxetumomab pasudotox MOXETUMOMAB PA...</td>\n",
       "      <td>[MOXETUMOMAB PASUDOTOX]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>2021</td>\n",
       "      <td>[FASENRA Benralizumab BENRALIZUMAB BENRALIZUMA...</td>\n",
       "      <td>[BENRALIZUMAB]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>2019</td>\n",
       "      <td>[CALQUENCE Acalabrutinib ACALABRUTINIB ACALABR...</td>\n",
       "      <td>[ACALABRUTINIB]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>2020</td>\n",
       "      <td>[NEXIUM Esomeprazole magnesium ESOMEPRAZOLE MA...</td>\n",
       "      <td>[ESOMEPRAZOLE MAGNESIUM]</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>2020</td>\n",
       "      <td>[MOVANTIK naloxegol oxalate NALOXEGOL OXALATE ...</td>\n",
       "      <td>[NALOXEGOL OXALATE]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>2021</td>\n",
       "      <td>[BRILINTA Ticagrelor TICAGRELOR TICAGRELOR MAN...</td>\n",
       "      <td>[TICAGRELOR]</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>2019</td>\n",
       "      <td>[SYMBICORT Budesonide and Formoterol Fumarate ...</td>\n",
       "      <td>[BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>2019</td>\n",
       "      <td>[KOMBIGLYZE XR SAXAGLIPTIN AND METFORMIN HYDRO...</td>\n",
       "      <td>[SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE]</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>2018</td>\n",
       "      <td>[Esomeprazole magnesium Esomeprazole magnesium...</td>\n",
       "      <td>[ESOMEPRAZOLE MAGNESIUM]</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    year                          spl_product_data_elements  \\\n",
       "0   2020  [SEROQUEL quetiapine QUETIAPINE FUMARATE QUETI...   \n",
       "1   2020  [Fulvestrant Fulvestrant FULVESTRANT FULVESTRA...   \n",
       "2   2019  [Budesonide and Formoterol Fumarate Dihydrate ...   \n",
       "3   2021  [BYDUREON BCise exenatide EXENATIDE EXENATIDE ...   \n",
       "4   2019  [PULMICORT RESPULES Budesonide BUDESONIDE BUDE...   \n",
       "5   2020  [QTERN dapagliflozin and saxagliptin DAPAGLIFL...   \n",
       "6   2020  [SEROQUEL XR quetiapine QUETIAPINE FUMARATE QU...   \n",
       "7   2019  [SymlinPen pramlintide acetate pramlintide ace...   \n",
       "8   2021  [Byetta exenatide exenatide exenatide metacres...   \n",
       "9   2019  [PULMICORT FLEXHALER Budesonide BUDESONIDE BUD...   \n",
       "10  2021  [TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB ...   \n",
       "11  2020  [BREZTRI budesonide, glycopyrrolate, and formo...   \n",
       "12  2021  [BYDUREON exenatide EXENATIDE EXENATIDE POLY(D...   \n",
       "13  2021  [FARXIGA DAPAGLIFLOZIN DAPAGLIFLOZIN PROPANEDI...   \n",
       "14  2021  [Lynparza olaparib OLAPARIB OLAPARIB HYPROMELL...   \n",
       "15  2021  [KOSELUGO SELUMETINIB SELUMETINIB SELUMETINIB ...   \n",
       "16  2021  [IRESSA Gefitinib GEFITINIB GEFITINIB LACTOSE ...   \n",
       "17  2020  [FASLODEX Fulvestrant FULVESTRANT FULVESTRANT ...   \n",
       "18  2021  [IMFINZI Durvalumab DURVALUMAB DURVALUMAB HIST...   \n",
       "19  2020  [LOKELMA sodium zirconium cyclosilicate SODIUM...   \n",
       "20  2020  [XIGDUO XR dapagliflozin and metformin hydroch...   \n",
       "21  2021  [Tudorza Pressair aclidinium bromide ACLIDINIU...   \n",
       "22  2020  [BEVESPI AEROSPHERE Glycopyrrolate and formote...   \n",
       "23  2020  [CRESTOR Rosuvastatin calcium ROSUVASTATIN CAL...   \n",
       "24  2020  [NEXIUM I.V. Esomeprazole sodium ESOMEPRAZOLE ...   \n",
       "25  2020  [Daliresp roflumilast roflumilast roflumilast ...   \n",
       "26  2021  [SAPHNELO Anifrolumab ANIFROLUMAB ANIFROLUMAB ...   \n",
       "27  2019  [LUMOXITI moxetumomab pasudotox MOXETUMOMAB PA...   \n",
       "28  2021  [FASENRA Benralizumab BENRALIZUMAB BENRALIZUMA...   \n",
       "29  2019  [CALQUENCE Acalabrutinib ACALABRUTINIB ACALABR...   \n",
       "30  2020  [NEXIUM Esomeprazole magnesium ESOMEPRAZOLE MA...   \n",
       "31  2020  [MOVANTIK naloxegol oxalate NALOXEGOL OXALATE ...   \n",
       "32  2021  [BRILINTA Ticagrelor TICAGRELOR TICAGRELOR MAN...   \n",
       "33  2019  [SYMBICORT Budesonide and Formoterol Fumarate ...   \n",
       "34  2019  [KOMBIGLYZE XR SAXAGLIPTIN AND METFORMIN HYDRO...   \n",
       "35  2018  [Esomeprazole magnesium Esomeprazole magnesium...   \n",
       "\n",
       "                                 openfda.generic_name  number_of_ingredients  \n",
       "0                                        [QUETIAPINE]                     19  \n",
       "1                                       [FULVESTRANT]                      1  \n",
       "2      [BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]                      1  \n",
       "3                                         [EXENATIDE]                      7  \n",
       "4                                        [BUDESONIDE]                      4  \n",
       "5                     [DAPAGLIFLOZIN AND SAXAGLIPTIN]                      3  \n",
       "6                                        [QUETIAPINE]                     13  \n",
       "7                               [PRAMLINTIDE ACETATE]                      1  \n",
       "8                                         [EXENATIDE]                      1  \n",
       "9                                        [BUDESONIDE]                      3  \n",
       "10                                      [OSIMERTINIB]                      5  \n",
       "11  [BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FU...                      4  \n",
       "12                                        [EXENATIDE]                     13  \n",
       "13                                    [DAPAGLIFLOZIN]                      3  \n",
       "14                                         [OLAPARIB]                      3  \n",
       "15                                      [SELUMETINIB]                      4  \n",
       "16                                        [GEFITINIB]                      3  \n",
       "17                                      [FULVESTRANT]                      1  \n",
       "18                                       [DURVALUMAB]                      1  \n",
       "19                   [SODIUM ZIRCONIUM CYCLOSILICATE]                      1  \n",
       "20        [DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE]                     11  \n",
       "21                               [ACLIDINIUM BROMIDE]                      1  \n",
       "22           [GLYCOPYRROLATE AND FORMOTEROL FUMARATE]                      2  \n",
       "23                             [ROSUVASTATIN CALCIUM]                      8  \n",
       "24                              [ESOMEPRAZOLE SODIUM]                      1  \n",
       "25                                      [ROFLUMILAST]                      5  \n",
       "26                                      [ANIFROLUMAB]                      1  \n",
       "27                            [MOXETUMOMAB PASUDOTOX]                      3  \n",
       "28                                     [BENRALIZUMAB]                      1  \n",
       "29                                    [ACALABRUTINIB]                      3  \n",
       "30                           [ESOMEPRAZOLE MAGNESIUM]                     15  \n",
       "31                                [NALOXEGOL OXALATE]                      3  \n",
       "32                                       [TICAGRELOR]                      3  \n",
       "33     [BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE]                      1  \n",
       "34          [SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE]                      4  \n",
       "35                           [ESOMEPRAZOLE MAGNESIUM]                      9  "
      ]
     },
     "execution_count": 101,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n[[\"year\",\"spl_product_data_elements\",\"openfda.generic_name\",'number_of_ingredients']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([2020, 2019, 2021, 2018], dtype=int64)"
      ]
     },
     "execution_count": 103,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n[\"year\"].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [],
   "source": [
    "js_n_PART_A= js_n.groupby(\"year\", as_index=False).agg({\"openfda.generic_name\":'sum',\"number_of_ingredients\":'mean'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>year</th>\n",
       "      <th>openfda.generic_name</th>\n",
       "      <th>number_of_ingredients</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2018</td>\n",
       "      <td>[ESOMEPRAZOLE MAGNESIUM]</td>\n",
       "      <td>9.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2019</td>\n",
       "      <td>[BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,...</td>\n",
       "      <td>2.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2020</td>\n",
       "      <td>[QUETIAPINE, FULVESTRANT, DAPAGLIFLOZIN AND SA...</td>\n",
       "      <td>6.214286</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2021</td>\n",
       "      <td>[EXENATIDE, EXENATIDE, OSIMERTINIB, EXENATIDE,...</td>\n",
       "      <td>3.538462</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   year                               openfda.generic_name  \\\n",
       "0  2018                           [ESOMEPRAZOLE MAGNESIUM]   \n",
       "1  2019  [BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,...   \n",
       "2  2020  [QUETIAPINE, FULVESTRANT, DAPAGLIFLOZIN AND SA...   \n",
       "3  2021  [EXENATIDE, EXENATIDE, OSIMERTINIB, EXENATIDE,...   \n",
       "\n",
       "   number_of_ingredients  \n",
       "0               9.000000  \n",
       "1               2.500000  \n",
       "2               6.214286  \n",
       "3               3.538462  "
      ]
     },
     "execution_count": 125,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n_PART_A"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['year', 'openfda.generic_name', 'number_of_ingredients'], dtype='object')"
      ]
     },
     "execution_count": 126,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n_PART_A.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [],
   "source": [
    "js_n_PART_A.columns=[\"year\",\"Drugs_names\",\"Avg. no of ingredients\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>year</th>\n",
       "      <th>Drugs_names</th>\n",
       "      <th>Avg. no of ingredients</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2018</td>\n",
       "      <td>[ESOMEPRAZOLE MAGNESIUM]</td>\n",
       "      <td>9.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2019</td>\n",
       "      <td>[BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,...</td>\n",
       "      <td>2.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2020</td>\n",
       "      <td>[QUETIAPINE, FULVESTRANT, DAPAGLIFLOZIN AND SA...</td>\n",
       "      <td>6.214286</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2021</td>\n",
       "      <td>[EXENATIDE, EXENATIDE, OSIMERTINIB, EXENATIDE,...</td>\n",
       "      <td>3.538462</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   year                                        Drugs_names  \\\n",
       "0  2018                           [ESOMEPRAZOLE MAGNESIUM]   \n",
       "1  2019  [BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE,...   \n",
       "2  2020  [QUETIAPINE, FULVESTRANT, DAPAGLIFLOZIN AND SA...   \n",
       "3  2021  [EXENATIDE, EXENATIDE, OSIMERTINIB, EXENATIDE,...   \n",
       "\n",
       "   Avg. no of ingredients  \n",
       "0                9.000000  \n",
       "1                2.500000  \n",
       "2                6.214286  \n",
       "3                3.538462  "
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "js_n_PART_A"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x268243d1d30>"
      ]
     },
     "execution_count": 140,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAW4AAAEWCAYAAABG030jAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nUh5GE7dSSnkYTdxKKeVh/h8b93MoyQYtFAAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x2682b898518>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "js_n_PART_A.plot(x='year', y='Avg. no of ingredients',title='Average no of ingredients used by AstraZeneca per year')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
